JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Robbie Marcus has maintained an Overweight rating on AtriCure (NASDAQ:ATRC) but has lowered the price target from $42 to $34.
May 02, 2024 | 4:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan maintains an Overweight rating on AtriCure but lowers the price target from $42 to $34.
The reduction in price target by JP Morgan, despite maintaining an Overweight rating, could lead to a negative short-term sentiment among investors, potentially impacting ATRC's stock price negatively.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100